Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Stephen Bloch sold 2,064 shares of the business's stock in a transaction on Friday, June 5th. The stock was sold at an average price of $64.14, for a total transaction of $132,384.96. Following the transaction, the director directly owned 1,785,242 shares in the company, valued at $114,505,421.88. This trade represents a 0.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Liquidia Price Performance
Shares of Liquidia stock opened at $63.90 on Tuesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $66.78. The firm has a fifty day moving average price of $47.32 and a two-hundred day moving average price of $39.87. The company has a market cap of $5.68 billion, a PE ratio of 456.46 and a beta of 0.57.
Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business's revenue was up 4187.1% on a year-over-year basis. Analysts expect that Liquidia Corporation will post 2.97 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on LQDA. Weiss Ratings restated a "sell (d-)" rating on shares of Liquidia in a research note on Tuesday, April 21st. Jefferies Financial Group reissued a "buy" rating and set a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Needham & Company LLC boosted their price objective on Liquidia from $54.00 to $70.00 and gave the company a "buy" rating in a research report on Monday, May 11th. Wells Fargo & Company upped their target price on Liquidia from $51.00 to $62.00 and gave the company an "overweight" rating in a research note on Tuesday, May 12th. Finally, BTIG Research raised their target price on Liquidia from $50.00 to $59.00 and gave the stock a "buy" rating in a research report on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Liquidia currently has a consensus rating of "Moderate Buy" and a consensus target price of $55.63.
Check Out Our Latest Stock Analysis on LQDA
Key Liquidia News
Here are the key news stories impacting Liquidia this week:
Hedge Funds Weigh In On Liquidia
Hedge funds have recently modified their holdings of the stock. Caprock Group LLC acquired a new stake in shares of Liquidia during the 3rd quarter worth about $37,114,000. Apis Capital Advisors LLC acquired a new position in Liquidia in the third quarter valued at about $9,569,000. Farallon Capital Management LLC boosted its position in Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company's stock valued at $194,783,000 after buying an additional 4,326,876 shares in the last quarter. GSA Capital Partners LLP grew its stake in Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company's stock worth $2,179,000 after buying an additional 24,555 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in Liquidia during the third quarter worth about $1,536,000. 64.54% of the stock is owned by institutional investors and hedge funds.
Liquidia Company Profile
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
